

# **Cancer Monoclonal Antibodies Market Report by Antibody Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, and Others), Medication Type (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbix), Panitumumab (Vectibix), and Others), Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Others), End-User (Hospitals and Clinics, Pharmacies, Research Laboratories, and Others), and Region 2024-2032**

<https://marketpublishers.com/r/C3E6F60E8E51EN.html>

Date: April 2024

Pages: 136

Price: US\$ 3,899.00 (Single User License)

ID: C3E6F60E8E51EN

## **Abstracts**

The global cancer monoclonal antibodies market size reached US\$ 46.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 64.6 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

#### Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on antibody type, medication type, end-user and application.

#### Breakup by Antibody Type:

- Murine Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Others

#### Breakup by Medication Type:

- Bevacizumab (Avastin)
- Rituximab (Rituxan)
- Trastuzumab (Herceptin)
- Cetuximab (Erbix)
- Panitumumab (Vectibix)
- Others

#### Breakup by Application:

Breast Cancer  
Blood Cancer  
Liver Cancer  
Brain Cancer  
Colorectal Cancer  
Others

Breakup by End-User:

Hospitals and Clinics  
Pharmacies  
Research Laboratories  
Others

Breakup by Region:

North America  
United States  
Canada  
Asia Pacific  
China  
Japan  
India  
South Korea  
Australia  
Others  
Europe  
Germany  
France  
United Kingdom  
Italy  
Spain  
Russia  
Others  
Latin America  
Brazil  
Mexico  
Others  
Middle East and Africa

### Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

### Key Questions Answered in This Report:

How has the global cancer monoclonal antibodies market performed so far and how will it perform in the coming years?

What are the key regional markets?

What has been the impact of COVID-19 on the global cancer monoclonal antibodies market?

What is the breakup of the market based on the antibody type?

What is the breakup of the market based on the medication type?

What is the breakup of the market based on the application?

What is the breakup of the market based on the end-user?

What are the various stages in the value chain of the industry?

What are the key driving factors and challenges in the industry?

What is the structure of the global cancer monoclonal antibodies market and who are the key players?

What is the degree of competition in the industry?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 INTRODUCTION**

- 4.1 Overview
- 4.2 Key Industry Trends

### **5 GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET**

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

### **6 MARKET BREAKUP BY ANTIBODY TYPE**

- 6.1 Murine Antibodies
  - 6.1.1 Market Trends
  - 6.1.2 Market Forecast
- 6.2 Chimeric Antibodies
  - 6.2.1 Market Trends
  - 6.2.2 Market Forecast
- 6.3 Humanized Antibodies

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
  - 6.4.1 Market Trends
  - 6.4.2 Market Forecast

## **7 MARKET BREAKUP BY MEDICATION TYPE**

- 7.1 Bevacizumab (Avastin)
  - 7.1.1 Market Trends
  - 7.1.2 Market Forecast
- 7.2 Rituximab (Rituxan)
  - 7.2.1 Market Trends
  - 7.2.2 Market Forecast
- 7.3 Trastuzumab (Herceptin)
  - 7.3.1 Market Trends
  - 7.3.2 Market Forecast
- 7.4 Cetuximab (Erbix)
  - 7.4.1 Market Trends
  - 7.4.2 Market Forecast
- 7.5 Panitumumab (Vectibix)
  - 7.5.1 Market Trends
  - 7.5.2 Market Forecast
- 7.6 Others
  - 7.6.1 Market Trends
  - 7.6.2 Market Forecast

## **8 MARKET BREAKUP BY APPLICATION**

- 8.1 Breast Cancer
  - 8.1.1 Market Trends
  - 8.1.2 Market Forecast
- 8.2 Blood Cancer
  - 8.2.1 Market Trends
  - 8.2.2 Market Forecast
- 8.3 Liver Cancer
  - 8.3.1 Market Trends
  - 8.3.2 Market Forecast
- 8.4 Brain Cancer

- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Colorectal Cancer
  - 8.5.1 Market Trends
  - 8.5.2 Market Forecast
- 8.6 Others
  - 8.6.1 Market Trends
  - 8.6.2 Market Forecast

## **9 MARKET BREAKUP BY END-USER**

- 9.1 Hospitals and Clinics
  - 9.1.1 Market Trends
  - 9.1.2 Market Forecast
- 9.2 Pharmacies
  - 9.2.1 Market Trends
  - 9.2.2 Market Forecast
- 9.3 Research Laboratories
  - 9.3.1 Market Trends
  - 9.3.2 Market Forecast
- 9.4 Others
  - 9.4.1 Market Trends
  - 9.4.2 Market Forecast

## **10 MARKET BREAKUP BY REGION**

- 10.1 North America
  - 10.1.1 United States
    - 10.1.1.1 Market Trends
    - 10.1.1.2 Market Forecast
  - 10.1.2 Canada
    - 10.1.2.1 Market Trends
    - 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
  - 10.2.1 China
    - 10.2.1.1 Market Trends
    - 10.2.1.2 Market Forecast
  - 10.2.2 Japan
    - 10.2.2.1 Market Trends

- 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Others
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.3 Europe
  - 10.3.1 Germany
    - 10.3.1.1 Market Trends
    - 10.3.1.2 Market Forecast
  - 10.3.2 France
    - 10.3.2.1 Market Trends
    - 10.3.2.2 Market Forecast
  - 10.3.3 United Kingdom
    - 10.3.3.1 Market Trends
    - 10.3.3.2 Market Forecast
  - 10.3.4 Italy
    - 10.3.4.1 Market Trends
    - 10.3.4.2 Market Forecast
  - 10.3.5 Spain
    - 10.3.5.1 Market Trends
    - 10.3.5.2 Market Forecast
  - 10.3.6 Russia
    - 10.3.6.1 Market Trends
    - 10.3.6.2 Market Forecast
  - 10.3.7 Others
    - 10.3.7.1 Market Trends
    - 10.3.7.2 Market Forecast
- 10.4 Latin America
  - 10.4.1 Brazil
    - 10.4.1.1 Market Trends
    - 10.4.1.2 Market Forecast



#### 10.4.2 Mexico

##### 10.4.2.1 Market Trends

##### 10.4.2.2 Market Forecast

#### 10.4.3 Others

##### 10.4.3.1 Market Trends

##### 10.4.3.2 Market Forecast

#### 10.5 Middle East and Africa

##### 10.5.1 Market Trends

##### 10.5.2 Market Breakup by Country

##### 10.5.3 Market Forecast

### **11 SWOT ANALYSIS**

#### 11.1 Overview

#### 11.2 Strengths

#### 11.3 Weaknesses

#### 11.4 Opportunities

#### 11.5 Threats

### **12 VALUE CHAIN ANALYSIS**

### **13 PORTERS FIVE FORCES ANALYSIS**

#### 13.1 Overview

#### 13.2 Bargaining Power of Buyers

#### 13.3 Bargaining Power of Suppliers

#### 13.4 Degree of Competition

#### 13.5 Threat of New Entrants

#### 13.6 Threat of Substitutes

### **14 COMPETITIVE LANDSCAPE**

#### 14.1 Market Structure

#### 14.2 Key Players

#### 14.3 Profiles of Key Players

##### 14.3.1 Amgen Inc.

##### 14.3.1.1 Company Overview

##### 14.3.1.2 Product Portfolio

##### 14.3.1.3 Financials

- 14.3.1.4 SWOT Analysis
- 14.3.2 Roche Holding AG
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
- 14.3.3 AbbVie Inc.
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Johnson & Johnson
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 Eli Lilly and Company
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Merck & Co. Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Genmab A/S
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 GlaxoSmithKline Plc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Bristol-Myers Squibb Company
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials

- 14.3.9.4 SWOT Analysis
- 14.3.10 Novartis AG
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis
- 14.3.11 Spectrum Pharmaceuticals Inc.
  - 14.3.11.1 Company Overview
  - 14.3.11.2 Product Portfolio
  - 14.3.11.3 Financials
  - 14.3.11.4 SWOT Analysis
- 14.3.12 Seattle Genetics Inc.
  - 14.3.12.1 Company Overview
  - 14.3.12.2 Product Portfolio
  - 14.3.12.3 Financials
  - 14.3.12.4 SWOT Analysis
- 14.3.13 Pfizer Inc.
  - 14.3.13.1 Company Overview
  - 14.3.13.2 Product Portfolio
  - 14.3.13.3 Financials
  - 14.3.13.4 SWOT Analysis

## List Of Tables

### LIST OF TABLES

Table 1: Global: Cancer Monoclonal Antibodies Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Antibody Type (in Million US\$), 2024-2032

Table 3: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Medication Type (in Million US\$), 2024-2032

Table 4: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Application (in Million US\$), 2024-2032

Table 5: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by End-User (in Million US\$), 2024-2032

Table 6: Global: Cancer Monoclonal Antibodies Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 7: Global: Cancer Monoclonal Antibodies Market: Competitive Structure

Table 8: Global: Cancer Monoclonal Antibodies Market: Key Players

## List Of Figures

### LIST OF FIGURES

Figure 1: Global: Cancer Monoclonal Antibodies Market: Major Drivers and Challenges

Figure 2: Global: Cancer Monoclonal Antibodies Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Cancer Monoclonal Antibodies Market: Breakup by Antibody Type (in %), 2023

Figure 4: Global: Cancer Monoclonal Antibodies Market: Breakup by Medication Type (in %), 2023

Figure 5: Global: Cancer Monoclonal Antibodies Market: Breakup by Application (in %), 2023

Figure 6: Global: Cancer Monoclonal Antibodies Market: Breakup by End-User (in %), 2023

Figure 7: Global: Cancer Monoclonal Antibodies Market: Breakup by Region (in %), 2023

Figure 8: Global: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 9: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 10: Global: Cancer Monoclonal Antibodies (Murine Antibodies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 11: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 12: Global: Cancer Monoclonal Antibodies (Chimeric Antibodies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 13: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 14: Global: Cancer Monoclonal Antibodies (Humanized Antibodies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 15: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 16: Global: Cancer Monoclonal Antibodies (Other Types of Antibodies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 17: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 18: Global: Cancer Monoclonal Antibodies (Bevacizumab) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 19: Global: Cancer Monoclonal Antibodies (Rituximab) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 20: Global: Cancer Monoclonal Antibodies (Rituximab) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 21: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 22: Global: Cancer Monoclonal Antibodies (Trastuzumab) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 23: Global: Cancer Monoclonal Antibodies (Cetuximab) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 24: Global: Cancer Monoclonal Antibodies (Cetuximab) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 25: Global: Cancer Monoclonal Antibodies (Panitumumab) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 26: Global: Cancer Monoclonal Antibodies (Panitumumab) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 27: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 28: Global: Cancer Monoclonal Antibodies (Other Medication Types) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 29: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 30: Global: Cancer Monoclonal Antibodies (Breast Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 31: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 32: Global: Cancer Monoclonal Antibodies (Blood Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 33: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 34: Global: Cancer Monoclonal Antibodies (Liver Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 35: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 36: Global: Cancer Monoclonal Antibodies (Brain Cancer) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 37: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 38: Global: Cancer Monoclonal Antibodies (Colorectal Cancer) Market Forecast:

Sales Value (in Million US\$), 2024-2032

Figure 39: Global: Cancer Monoclonal Antibodies (Other Applications) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 40: Global: Cancer Monoclonal Antibodies (Other Applications) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 41: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 42: Global: Cancer Monoclonal Antibodies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 43: Global: Cancer Monoclonal Antibodies (Pharmacies) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 44: Global: Cancer Monoclonal Antibodies (Pharmacies) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 45: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 46: Global: Cancer Monoclonal Antibodies (Research Laboratories) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 47: Global: Cancer Monoclonal Antibodies (Others) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 48: Global: Cancer Monoclonal Antibodies (Others) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 49: North America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 50: North America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 51: United States: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 52: United States: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 53: Canada: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 54: Canada: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 55: Asia Pacific: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 56: Asia Pacific: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 57: China: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 58: China: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 59: Japan: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 60: Japan: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 61: India: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 62: India: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 63: South Korea: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 64: South Korea: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 65: Australia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 66: Australia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 67: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 68: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 69: Europe: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 70: Europe: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 71: Germany: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 72: Germany: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 73: France: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 74: France: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 75: United Kingdom: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 76: United Kingdom: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 77: Italy: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$),



2018 & 2023

Figure 78: Italy: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 79: Spain: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 80: Spain: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 81: Russia: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 82: Russia: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 83: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 84: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 85: Latin America: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 86: Latin America: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 87: Brazil: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 88: Brazil: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 89: Mexico: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 90: Mexico: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 91: Others: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 92: Others: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 93: Middle East and Africa: Cancer Monoclonal Antibodies Market: Sales Value (in Million US\$), 2018 & 2023

Figure 94: Middle East and Africa: Cancer Monoclonal Antibodies Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 95: Global: Cancer Monoclonal Antibodies Industry: SWOT Analysis

Figure 96: Global: Cancer Monoclonal Antibodies Industry: Value Chain Analysis

Figure 97: Global: Cancer Monoclonal Antibodies Industry: Porter's Five Forces Analysis

## I would like to order

Product name: Cancer Monoclonal Antibodies Market Report by Antibody Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, and Others), Medication Type (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbix), Panitumumab (Vectibix), and Others), Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, and Others), End-User (Hospitals and Clinics, Pharmacies, Research Laboratories, and Others), and Region 2024-2032

Product link: <https://marketpublishers.com/r/C3E6F60E8E51EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3E6F60E8E51EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970